Amyris

Bankruptcy Filings up to the 3rd quarter of 2023 exceed total filings for 2021 and 2022

Retrieved on: 
Thursday, October 5, 2023
Diamond, Aircraft, Medicine, Envision Healthcare, Real estate, Yellow Corporation, Environment, Bed, YTD, Chapter 15, Title 11, United States Code, Moelis & Company, Jefferies Group, Diamond Sports Group, Mallinckrodt, FTI, A&M, Chapter 22, Investment company, Western Global Airlines, Chapter 33 (G.I. Bill of Rights), Currency crisis, Jefferies, Investment banking, Health care, Evercore, Bankruptcy, Guggenheim, McDermott Will & Emery, Data, Amyris, Adviser, Guggenheim Partners, Sale, Multimedia, Dundon, Quarter, Huntsman Corporation, Mace Head Atmospheric Research Station, National CineMedia, Construction, Cryptocurrency, Liability

BOSTON, Oct. 5, 2023 /PRNewswire-PRWeb/ -- According to Data compiled by New Generation Research's BankruptcyData, Bankruptcy Filings as of the end of the Quarter ended September 31, 2023, totaled 7518 year to date. This is the highest rate of bankruptcy since 2020, up sharply from last year. The total number of filings YTD in 2023 exceeds all filings for both 2021 and 2022, and is on a pace which rivals the activity of 2020, itself was a record year unequaled since the days of the Global Financial Crisis.

Key Points: 
  • BOSTON, Oct. 5, 2023 /PRNewswire-PRWeb/ -- According to Data compiled by New Generation Research's BankruptcyData , Bankruptcy Filings as of the end of the Quarter ended September 31, 2023, totaled 7518 year to date.
  • So far in 2023, there have been such filings versus 383 for all of 2022, an increase of over 70%, and there are still three months to go in 2023.
  • Also, the number of companies doing a round trip to Bankruptcy court among public and large private companies has risen markedly in 2023.
  • The pace of filings has been trending upwards during the course of the year as the graph below indicates.

Delisting of Securities of Nymox Pharmaceutical Corporation; Aridis Pharmaceuticals Inc.; Novan, Inc.; ViewRay, Inc.; 9 Meters Biopharma, Inc.; Nabriva Therapeutics plc; UTA Acquisition Corporation; AppHarvest, Inc.; Yellow Corporation; Proterra Inc.; Amy

Retrieved on: 
Thursday, September 7, 2023
Amyris, Appharvest, UTA, Proterra (bus manufacturer), Novin, Yellow Corporation, Therapy, Cryptocurrency

Nymox Pharmaceutical Corporation’s securities were suspended on July 7, 2023, and have not traded on Nasdaq since that time.

Key Points: 
  • Nymox Pharmaceutical Corporation’s securities were suspended on July 7, 2023, and have not traded on Nasdaq since that time.
  • Nasdaq also announced today that it will delist the common stock of Aridis Pharmaceuticals Inc. Aridis Pharmaceuticals Inc.’s securities were suspended on July 19, 2023, and have not traded on Nasdaq since that time.
  • Nasdaq also announced today that it will delist the ordinary shares of Nabriva Therapeutics plc.
  • Nabriva Therapeutics plc’s securities were suspended on August 1, 2023, and have not traded on Nasdaq since that time.

Modern Health Central™ Offers Organizations a Single, Unified Platform to Elevate How Employers Understand, Cultivate, and Scale Workplace Well-Being

Retrieved on: 
Wednesday, July 26, 2023
Professional Services, Health, Human Resources, Mental Health, Well, Customer success, Communication, ERG, Face, Culture, Lockton Companies, Workplace, WTW, McDonnell Aircraft Corporation, Atomic emission spectroscopy, DEIB, Privacy, Kaiser Permanente, Cigna, Harmon, HR, Employee resource group, SVP, Mental health, PacifiCare Health Systems, Partnership, Nursing, Management, Creative industries, Risk management, Traditional and Modern Health Practitioners Together against AIDS, Amyris, UnitedHealth Group

Modern Health , a leading global workplace mental health platform, today announces the launch of Modern Health Central™, a new enhanced employer hub for workplace well-being.

Key Points: 
  • Modern Health , a leading global workplace mental health platform, today announces the launch of Modern Health Central™, a new enhanced employer hub for workplace well-being.
  • Modern Health has evolved its employer Insights Hub to create an industry-defining platform for employers to scale employee well-being and meet evolving expectations.
  • Surgeon General released a Workplace Mental Health Framework intended to be a national call to action for employers to prioritize employee well-being.
  • The focus on workplace mental health has never been clearer, but not all employers are equipped to navigate this emerging landscape.

AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

Retrieved on: 
Monday, June 26, 2023
PwC, Amyris, Chairperson, Interim, Amyris (company), Management

The Company also announced a global reduction in force as an important step towards its previously announced cost reduction targets.

Key Points: 
  • The Company also announced a global reduction in force as an important step towards its previously announced cost reduction targets.
  • "We have utmost confidence in Han's ability to lead Amyris as Interim Chief Executive Officer through this critical period of transformation."
  • "We are making tough choices including the decision to implement a reduction in force which we are executing today.
  • We thank our departing employees for their efforts, dedication and contributions to Amyris," said Han Kieftenbeld, Interim Chief Executive Officer and Chief Financial Officer of Amyris.

AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE

Retrieved on: 
Friday, May 19, 2023
Partnership, Administration, Squalene, Sustainability, Sale, Shark, Beauty, CGMP, Health, International, Vaccine, Pharmaceutical industry, Croda International, Amyris

Amyris' squalene is a biofermentation-based adjuvant developed using Amyris' unique Lab-to-Market technology platform.

Key Points: 
  • Amyris' squalene is a biofermentation-based adjuvant developed using Amyris' unique Lab-to-Market technology platform.
  • Amyris' sugarcane-derived, sustainable squalene is molecularly identical to the traditional shark source, offering a higher purity and a more predictable cost profile compared to sourcing directly from sharks.
  • Under the terms of the agreement, Amyris will manufacture and supply squalene to Croda and Croda will license squalene technology from Amyris to market, distribute, and sell squalene as an excipient, or as an ingredient in formulated products for use in human and veterinary vaccines, drug delivery systems, or nucleic acid delivery systems.
  • "We are pleased to partner with Croda to increase access to our sustainable squalene.

AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9

Retrieved on: 
Tuesday, May 2, 2023
Amyris, Webcast, Management, Drug

EMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets.

Key Points: 
  • EMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets.
  • The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo, President and Chief Executive Officer, and Han Kieftenbeld, Chief Financial Officer, will discuss Amyris' financial results and provide an update on the company's business.
  • Participants may access the live webcast on Amyris' Investor Relations website, where it will be archived for 90 days.
  • The live call can be accessed by dialing (844) 850-0551 (domestic) or (412) 902-4203 (international) and asking to join the Amyris, Inc. call.

AMYRIS CLOSES STRATEGIC TRANSACTION WITH GIVAUDAN

Retrieved on: 
Wednesday, April 5, 2023
Earnout, Partnership, Beauty, History, Fine chemical, Amyris, Givaudan

EMERYVILLE, Calif., April 5, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, announced that it has completed the previously announced strategic transaction with Givaudan SA for the worldwide exclusive licensing of certain cosmetic ingredients, including Neossance® Squalane, the highest performant emollient, Neossance® Hemisqualane, the plant-based silicone alternative, and CleanScreen™, the sustainable sun protector.

Key Points: 
  • Givaudan is a global leader in Fragrance & Beauty.
  • Amyris and Givaudan have a strong partnership to leverage the value of Amyris' technology platform for designing, scaling and manufacturing the best-performing bio-fermented ingredients.
  • This marketing partnership builds on a successful history that includes the development and commercialization of the world's leading supply of Bisabolol from Amyris' precision fermentation platform.
  • "We are very pleased with the expansion of our long-term partnership with Givaudan," said John Melo, President and Chief Executive Officer.

WILLOW BIOSCIENCES ANNOUNCES CHANGES TO BOARD AND MANAGEMENT

Retrieved on: 
Tuesday, March 28, 2023
Precigen, Xavier University, LLP, Lead, Codexis, University, Genetic engineering, Willow Springs Distilling Company, Army Science Board, PwC, Barr Pharmaceuticals, AGM, Certified Public Accountant, CBG, Development, Amyris, Partner, Chris, TSX, Growth, CFO, Research, WLLW, Compensated emancipation, Management, Willow

Since joining Willow, Dr. Savile has led the development of the technology platform, building of the operational capabilities, and expansion of the internal portfolio and external partnerships.

Key Points: 
  • Since joining Willow, Dr. Savile has led the development of the technology platform, building of the operational capabilities, and expansion of the internal portfolio and external partnerships.
  • Prior to joining Willow, Dr. Savile worked in senior leadership roles at Intrexon Corporation, a biotechnology company, and Codexis, Inc., a protein engineering company.
  • "Chris' extensive scientific knowledge and business development experience will be invaluable to Willow in its next phase of growth," said Trevor Peters, Chairman of the Board.
  • "Willow is grateful to Dr. Seufer-Wasserthal's vision and talent," said Trevor Peters, Chairman of the Board of the Company.

AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 15, 2023

Retrieved on: 
Tuesday, February 28, 2023
Webcast, Amyris, Cryptocurrency, Management, Drug

EMERYVILLE, Calif., Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2022, on the afternoon of Wednesday, March 15, 2023, after closing of the financial markets.

Key Points: 
  • EMERYVILLE, Calif., Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2022, on the afternoon of Wednesday, March 15, 2023, after closing of the financial markets.
  • The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo, President and Chief Executive Officer, and Han Kieftenbeld, Chief Financial Officer, will discuss Amyris' financial results and provide an update on the company's business.
  • Participants may access the live webcast on Amyris' Investor Relations website, where it will be archived for 90 days.
  • The live call can be accessed by dialing (844) 850-0551 (domestic) or (412) 902-4203 (international) and asking to join the Amyris, Inc. call.

GIVAUDAN TO ACQUIRE PORTFOLIO OF MAJOR COSMETIC INGREDIENTS FROM AMYRIS AND TO ESTABLISH STRATEGIC PARTNERSHIP FOR NATURAL, SUSTAINABLY SOURCED INGREDIENTS FOR THE BEAUTY INDUSTRY

Retrieved on: 
Wednesday, February 22, 2023
Biotechnology, Flavor, International Flavors & Fragrances, Partnership, Growth, Wellness, Environment, Earnout, Cosmetics, Perfume, Fine chemical, Beauty, Amyris, Givaudan

EMERYVILLE, Calif., Feb. 22, 2023 /PRNewswire/ -- As part of its 2025 strategy to provide new and superior product offerings to expand its Active Beauty business, Givaudan, the global leader in fragrance & beauty innovation, today announces that it has reached an agreement to acquire certain cosmetic ingredients from Amyris, Inc. (Nasdaq: AMRS), including Neossance® Squalane, the highest performant emollient, Neossance® Hemisqualane, the plant-based silicone alternative and CleanScreen, the sustainable sun protector.

Key Points: 
  • Givaudan and Amyris have signed a long-term partnership agreement under which Amyris will continue to manufacture ingredients for Givaudan to use in cosmetics, as well as provide access to their innovation capabilities.
  • Givaudan will become the commercialization partner for future sustainable beauty ingredients.
  • Amyris and Givaudan have a significant partnership to leverage the value of Amyris' technology platform for designing, scaling and manufacturing the best performing biofermented ingredients.
  • Markus Rassmann, Head of Active Beauty, said: "Today, we have the widest offering of biotech cosmetic ingredients on the market.